Background: Collecting duct carcinoma (CDC) is a rare and aggressive subtype of kidney cancer that responds to platinum-based chemotherapy. Recent phase II trials have established enhanced antitumor activity on combining bevacizumab with chemotherapy in patients with metastatic urothelial carcinoma, a tumor that shares many features with CDC. Our aim was to investigate whether combining bevacizumab with platinum-based chemotherapy might not also show promise in metastatic CDC (mCDC) patients.
introduction
Renal cell carcinoma (RCC) is the most common type of kidney cancer, with an estimated incidence of 88 400 new cases each year in Europe [1] . Incidence is increasing by about 2% annually. The clear-cell subtype (ccRCC) accounts for 75% of RCCs. The remaining 25% include papillary, chromophobe, collecting duct, medullary, Xp11.2 translocation and unclassified RCC [2] .
Collecting duct carcinoma (CDC), recognized as a separate entity in 1986, accounts for <1% of all kidney carcinomas [3] . It is an aggressive subtype that does not respond to conventional RCC treatments such as immunotherapy [4] . It shares common morphological and biological characteristics with urothelial carcinomas and responds similarly to platinum-based chemotherapy [5] . In a 2007 prospective phase II trial, we observed convincing evidence of efficacy in patients with previously untreated metastatic CDCs (mCDC) on treatment with gemcitabine and platinum salt [6] .
As two recent phase II trials have shown enhanced antitumor activity on combining bevacizumab with chemotherapy in patients with metastatic urothelial carcinoma, we investigated whether the addition of bevacizumab to our gemcitabine-platinum salt combination might not also show promise in mCDC patients [7, 8] . Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). [9] ). All five patients had metastatic disease. The sites of secondary lesions were the lymph nodes (n = 2), lung (n = 2), liver (n = 1) and bone (n = 1). All five patients had undergone radical nephrectomy but none had received prior systemic treatment for their disease. All had an Eastern Cooperative Oncology Group Performance status of 0-1. Prognosis was classified as good (n = 1) and intermediate (n = 4) according to the Motzer score [10] , and as favorable (n = 2), intermediate (n = 1) or poor (n = 2) according to the more recent Heng score [11] .
Patients received first-line treatment with the bevacizumabgemcitabine-platinum salt combination for a median of four cycles (range, 2-6). This was followed by maintenance therapy with bevacizumab alone for a median of three cycles (range, 0-17). Median PFS was 15.1 months [95% confidence interval (CI) 5.6-20.4] and median OS was 27.8 months (95% CI 12.4-unreached).
Three of the five patients had a confirmed partial response (objective response rate, 60%) ( Figure 1 ). The PFS of these responding patients was 5.6, 6.7 and 15.1 months; their OS was 12.4, 13.2 and 27.8 months. A fourth patient, with an intermediate prognostic score and only lung metastases, who discontinued the triple combination after four cycles for reasons of patient preference, showed stable disease over 20 months and is still alive after 47 months of follow-up despite radiological tumor progression. The last patient, with stable disease after two treatment cycles, discontinued treatment because of grade 4 asthenia. After surgical resection of the sole positive metastatic site, a mediastinal lymph node confirmed by histologic examination, this patient is in complete remission after 16 months of follow-up.
Clinically relevant adverse events (Table 2) included the above-mentioned case of grade 4 asthenia leading to treatment interruption after two cycles and two cases of asymptomatic grade 3 pulmonary embolism. Bevacizumab was not withdrawn in these two patients despite administration of anticoagulation therapy. No complications occurred. There was one case of grade 4 neutropenia and one of grade 4 thrombopenia. Hypertension was mild and manageable. There were no cases of either renal failure or hemorrhage. No treatment-related death was observed.
discussion
Most current knowledge on CDCs comes from small retrospective series with a mean patient age of 55 years at diagnosis and an M:F sex ratio of 2:1 [12] . According to a recent study, CDC might be more frequent among African-Americans than Caucasians [13] . Patients usually present with abdominal pain and a flank mass, and sometimes with hematuria. CDCs are aggressive, often locally advanced (mean primary size of 94 mm) and have a poor prognosis [14, 15] . In the largest reported series of 81 CDC cases (32% metastatic, 44% with lymph node involvement), the 5-year survival rate was 34.3% [16] . On analysis of the Surveillance, Epidemiology and End Results (SEER) database for the years 2001 to 2005, i.e. before the introduction of antiangiogenic drugs, mortality for CDC was 2.42-fold higher than for ccRCC [13] .
Key histopathological features of CDC include development from the renal medulla, presence of an infiltrative tubular or tubulopapillary pattern, frequent nuclear and mitotic atypia and desmoplastic stromal reaction [17] . Histochemistry with Ulex europeus agglutinin or peanut lectin is usually positive as is frequently immunohistochemistry with markers such as vimentin, e-cadherin, c-KIT and cytokeratins (high or low molecular weight). On the other hand, markers of proximal renal tubules (CD10, RCC antigen and AMACR) are almost always negative [18, 19] . Interestingly, HER2 amplification was identified in 45% (n = 5/11) of the CDCs, and this condition was associated with poor survival [20] .
The definition of CDCs has been fine-tuned over recent years by exclusion of two low-grade subtypes with a good prognosis, namely tubulocystic carcinomas, which are closer to papillary RCCs, and mucinous tubular and spindle cell carcinomas [21] . Although renal medullary carcinoma, which occurs in patients with sickle-cell disease and has a very poor prognosis, has many overlapping features with CDC, it is, unlike CDC, characterized [22, 23] . CDC is also thought to share features with urothelial carcinomas, as suggested by cases of concurrent urothelial and CDCs, making differential diagnosis between these tumors difficult [5, 24] . Currently, there is no standard of care for CDCs. Radical nephrectomy is usually carried out for both diagnostic and therapeutic purposes [16] . Patients with negative nodes and no metastatic disease have been shown to benefit from surgery ( postoperative survival rates of over 8 years) [14] . Surgery is not recommended in patients with node involvement or distant metastasis as the survival rate is <1 year and perioperative mortality is high for large primary tumors [14, 25, 26] .
Platinum-based chemotherapy of CDC (e.g. methotrexate, vinblastine, doxorubicin and cisplatin or cisplatin-gemcitabine) has shown some efficacy in small patient series but has not been evaluated in clinical trials until recently [25] [26] [27] . A prospective phase II trial of first-line gemcitabine combined with platinum salt in mCDC patients was published in 2007 [6] . The response rate was 26%, median PFS was 7.1 months (95% CI 3-11.3) and median OS was 10.5 months (95% CI 3.8-17.1). These good outcomes suggested that chemotherapy could be used as standard therapy in patients with advanced disease and as postoperative adjuvant therapy in patients with lymph node involvement.
Targeted therapies tested in mCDC are kinase inhibitors targeting either VEGF receptor (VEGF-R) (sunitinib or sorafenib) or mammalian target of rapamycin (mTOR) (temsirolimus) or monoclonal antibodies targeting HER2/neu receptor (trastuzumab) or VEGF-R (bevacizumab). Some encouraging case reports have been published (Table 3 ). The present report has described the addition of bevacizumab to a platinum-based combination in mCDC patients with a good performance status. This combination has already been shown to be safe and effective in phase II trials in patients with urothelial carcinoma [7, 8] . All our five patients experienced clinical benefit. Response rate, median PFS and median OS were more than double those recorded for just gemcitabine + platinum salt (Table 3 ) [6] . The treatment was associated with manageable adverse events. However, a major limitation of this report, as of many others, is the small sample size and results will need to be confirmed in a prospective clinical trial.
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